Cancer inpatients with COVID-19

als.fakia shared this article with you from Inoreader Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute Via PLOS ONE Alerts: New Articles by Andreia C. de Melo, Luiz C. S. Thuler, Jesse L. da Silva, Lucas Z. de Albuquerque, Ana C. Pecego, Luciana de O. R. Rodrigues, Magda S. da Conceição, Marianne M. Garrido, Gelcio L. Quintella Mendes, Ana Cristina P. Mendes Pereira, Marcelo A. Soares, João P. B. Viola, on behalf of the Brazilian National Cancer Institute COVID-19 Task Force Objective This study aimed to describe the demographic and clinical characteristics of cancer inpatients with COVID-19 exploring clinical outcomes. Methods A retrospective search in the electronic medical records of cancer inpatients admitted to the Brazilian National Cancer Institute from April 30, 2020 to May 26, 2020 granted identification of 181 patients with COVID-19 confirmed by RT-PCR. Results The mean age was 55.3 years (SD ± 21.1). Comorbidities were present in 110 (60.8%) cases. The most prevalent solid tumors were breast (40 [22.1%]), gastrointestinal (24 [13.3%]), and gynecological (22 [12.2%]). Among hematological malignancies, lymphoma (20 [11%]) and leukemia (10 [5.5%]) predominated. Metastatic disease accounted for 90 (49.7%) cases. In total, 63 (34.8%) had recently received cytotoxic chemotherapy. The most common complications were respiratory failure (70 [38.7%]), septic shock (40 [22.1%]) and acute kidney injury (33 [18.2%]). A total of 60 (33.1%) patients died due to COVID-19 complications. For solid tumors, the COVID-19-specific mortality rate was 37.7% (52 out of 138 patients) and for hematological malignancies, 23.5% (8 out of 34). According to the univariate analysis COVID-19-specific mortality was significantly associated with age over 75 years (P = .002), metastatic cancer (p Conclusion This is the first Brazilian cohort of cancer patients with COVID-19. The rates of complications and COVID-19-specific death were significantly high. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.